ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Engineered Mesenchymal Stem Cell-NK Cell Complexes for Spatially Targeted and Functionally Revitalized Cancer Immunotherapy.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Nanoparticles-enhanced CAR-T cell therapy: current advances and future directions.Biomarker research · 2026Review
- Click Chemistry Mediated Immune Synapse Augmentation in Natural Killer Cell-Cancer Membrane Engagement and Facilitated Anticancer Efficacies of Natural Killer Cell Therapy.Biomaterials research · 2026Article
- Advances in immunotherapy for thyroid malignancies: from molecular targets to clinical outcomes.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Natural killer (NK) cells represent a powerful immunotherapeutic strategy due to their intrinsic cytotoxicity and ability to target tumor cells independently of antigen presentation. However, their clinical efficacy against solid tumors is limited by poor tumor infiltration and impaired functionality within the immunosuppressive microenvironment. Here, a genetically engineered cell-cell complex delivery system comprising NK cells conjugated to IL-15 expressing adipose-derived mesenchymal stem cells (SCs) is developed. By exploiting SCs' intrinsic tumor-tropic properties and engineering them to consistently express interleukin-15 (IL-15) via lipid nanoparticle-mediated mRNA transfection, the SC-NK cell complexes exhibit markedly improved tumor localization and sustained cytokine-mediated functional enhancement. Utilizing bioorthogonal click chemistry for precise conjugation, the approach effectively enhances NK cell infiltration and revitalizes their cytotoxic activity in both orthotopic murine lung cancer and patient-derived xenograft ovarian cancer models. Furthermore, increased responsiveness of the cell-cell complexes to Galectin-9 blockade therapy is identified, leading to the reversal of NK cell dysfunction and significantly augmented antitumor efficacy. Collectively, the engineered SC-assisted delivery system holds potential for overcoming the limitations of NK cell therapies and improving their therapeutic outcomes in solid tumor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.